NCT06738680Not yet recruiting
PRedictive Value of Multiparametric Dynamic WB 18F-FDG-PET Imaging on a LAFOV System for FIRST-line Chemo-immunotherapy Efficacy in Advanced Non-small-cell Lung Cancer: PROFIL-1
PRedictive Value of Multiparametric Dynamic Whole-body 18F-FDG-PET Imaging on a LAFOV System for FIRST-line Chemo-immunotherapy Efficacy in Advanced Non-small-cell Lung Cancer: PROFIL-1 Study
Source: ClinicalTrials.gov · Last updated 18 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Lung cancer is the leading cause of cancer deaths worldwide. Revolution of chemo-immunotherapy (CT-IO) in first-line of metastatic non-small-cell lung cancers (NSCLC) without actionable genomic alterations (AGAs) has dramatically improved prognosis, providing long response to a subset of patients. Because of a highly heterogeneous disease, majority of patients do not show long term benefit. Long axial field of view positron emission tomography (LAFOV-PET) scanner is a new emerging system allowing dynamic whole-body imaging with higher sensitivity, representing unique opportunity for oncological applications. The aim of this study is to determine if LAFOV-PET imaging biomarkers could early predict response to CT-IO in NSCLC.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 15 Nov 2024
- Start date
- 30 Jan 2025
- Primary completion date
- 30 Jan 2026
- Lead sponsor
- University Hospital, Brest
- Diseases
- Lung cancer
- NCT number
- NCT06738680
What you commit to
- Study type: Observational
- Planned participants: 120
- From 30 Jan 2025 to the primary completion date, 30 Jan 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Ineligible for first-line chemo-immunotherapy
Lab values
- Oncogenic addiction targetable in 1st line: EGFR, ALK, ROS1, RET
Age
- Minor patients \<18 years
Other
- Pregnancy or breast-feeding
- Other histology than NSCLC
- PET-FDG Scan contraindications
- Refusal to participate
Who the study is looking for
- Adult patients ≥ 18 years
- With advanced, non-operable, non-radiatable or metastatic NSCLC
- Treatment-naïve patients
- Eligible for first-line chemo-immunotherapy (anti-PD-1)
- Written Non-objection
- Eligible for LAFOV FDG-PET less than 21 days before initiation of treatment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brest University Hospital Coordinator of this site? Confirm its status | Brest | France | Unknown status |
| Morlaix Hospital Center Coordinator of this site? Confirm its status | Morlaix | France | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.